戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nce effects of sex in the Cardiovascular and Pharmacogenetics study.
2 ed populations, which can be used for future pharmacogenetic studies.
3 ance of maximizing adherence to treatment in pharmacogenetic studies.
4 here to the STROPS guideline when publishing pharmacogenetic studies.
5 ns of drug metabolism in epidemiological and pharmacogenetic studies.
6 lso report some of the initial findings from pharmacogenetic studies.
7  clinical information collected from ongoing pharmacogenetic studies.
8                                              Pharmacogenetic studies aiming to personalize the treatm
9  to improve the transparency of reporting of pharmacogenetic studies and also to facilitate the condu
10                                   Currently, pharmacogenetic studies are at an impasse as the low pre
11                                              Pharmacogenetics studies are the platform for discoverin
12                                              Pharmacogenetic studies can be conducted in multicenter
13                    Genetic sequence data for pharmacogenetics studies can be complex, and the best in
14          An 8-week, double-blind, randomized pharmacogenetic study compared the widely prescribed ant
15                                         This pharmacogenetic study evaluated the impact of high-risk
16 the DPYD gene and should be useful in future pharmacogenetic studies examining DPD deficiency.
17                 The model was validated by a pharmacogenetic study for two predominant beta-adrenergi
18 morphisms (SNPs) in clinical association and pharmacogenetic studies has created a need for high-thro
19                                     To date, pharmacogenetic studies have been primarily performed in
20                                              Pharmacogenetic studies have reported inconsistent linka
21                                              Pharmacogenetic studies have shown that polymorphisms of
22                         Importance: Previous pharmacogenetic studies have shown the prognostic impact
23                                      Several pharmacogenetics studies have identified an association
24 rom non-responders via genetic predictors in pharmacogenetics studies have not met their anticipated
25                                              Pharmacogenetic studies hold the promise of being able t
26 his assay may be useful to complement future pharmacogenetic studies in asthma.
27                                              Pharmacogenetic studies in larger cohorts are needed to
28                                       Recent pharmacogenetic studies in mood disorders have reported
29                                              Pharmacogenetic studies in palliative care are challengi
30 ould pave the way for the next generation of pharmacogenetic studies in psychiatry.
31 hese data may provide proof-of-principle for pharmacogenetic studies in schizophrenia.
32 ant that samples be collected and stored for pharmacogenetic study in future clinical trials.
33 these findings demonstrate the importance of pharmacogenetics studies in veterinary species and sugge
34 mine treatment in a prospective double-blind pharmacogenetics study in first-generation Mexican Ameri
35 s: in vivo pharmacokinetics studies, in vivo pharmacogenetic studies, in vivo drug interaction studie
36 NP-drug response association dataset for 650 pharmacogenetic studies involving 257 drugs in this upda
37 er, performing robust synthesis of data from pharmacogenetic studies is often challenging because of
38                                   Concerning pharmacogenetic studies, no association was found for th
39                                              Pharmacogenetic studies of admixed ethnic groups have be
40  common ethnic groups and facilitate applied pharmacogenetic studies of anticancer drugs.
41 etic studies, review the first generation of pharmacogenetic studies of psychotropic drug response, a
42  selective antagonists for further molecular pharmacogenetic studies of the human prostacyclin recept
43 We conducted a multicenter observational and pharmacogenetic study of 200 patients with DLE treated w
44 participated in a prospective, double-blind, pharmacogenetic study of antidepressant response, and 33
45     We conducted a randomized, double-blind, pharmacogenetic study of behavioral therapy and sibutram
46                           Here we describe a pharmacogenetic study of Li(+) in the nematode Caenorhab
47                                   An initial pharmacogenetic study of the Sequenced Treatment Alterna
48 ed by Genetic Haplotype Markers) study was a pharmacogenetics study of statin efficacy and safety.
49                               Candidate gene pharmacogenetic studies offer a strategy for the rapid a
50 context of rare diseases, with much focus on pharmacogenetic studies, owing to the cause of these dis
51  authors discuss methods issues in executing pharmacogenetic studies, review the first generation of
52 o develop the STrengthening the Reporting Of Pharmacogenetic Studies (STROPS) guideline.
53  currently no guideline for the reporting of pharmacogenetic studies that has been developed using a
54 nally, the authors discuss unique aspects of pharmacogenetic studies that may distinguish them from s
55 l, Costa-Mattioli et al. present data from a pharmacogenetic study that places a key regulatory event
56 was performed on data from three genome-wide pharmacogenetic studies (the Genome-Based Therapeutic Dr
57 ssion Network [DeNT] study; N=332), and 3) a pharmacogenetic study (the Genome-Based Therapeutic Drug
58 be clearly defined and justified, because in pharmacogenetic studies, there may be a greater number o
59                                Although most pharmacogenetic studies to date have assessed the associ
60 enome-wide analyses may complement candidate pharmacogenetic studies to identify risk markers of adve
61   This is the largest and most comprehensive pharmacogenetics study to date examining clinical respon
62                                        Prior pharmacogenetic studies usually measure exposure via sin
63                           Additional, larger pharmacogenetic studies would help to validate these res